Role of proteases in pancreatic carcinoma

World Journal of Surgery

Volumn 29, Issue 3, 2005, Pages 258-263

  Patten, Lane C ^a,b   Berger, David H ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BATIMASTAT; GEMCITABINE; MARIMASTAT; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; PRINOMASTAT; PROTEINASE; SERINE PROTEINASE; TANOMASTAT;

CANCER INVASION; CLINICAL TRIAL; CONFERENCE PAPER; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; METASTASIS; MUSCULOSKELETAL DISEASE; PANCREAS CARCINOMA; PROGNOSIS; SIDE EFFECT; TUMOR GROWTH;

HUMANS; MATRIX METALLOPROTEINASES; PANCREATIC NEOPLASMS; PROGNOSIS; SERINE ENDOPEPTIDASES; SERINE PROTEINASE INHIBITORS;

EID: 20044380381     PISSN: 03642313     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00268-004-7816-3     Document Type: Conference Paper

References (76)

1. AB Lowenfels P Maisonneuve 2002 Epidemiologic and etiologic factors of pancreatic cancer Hematol. Oncol. Clin. North Am. 16 1 16
2. American Cancer Society Facts and Figures ( www.cancer.org )
3. T Nagakawa I Konishi Y Higashino 1989 The spread and prognosis of carcinoma in the region of the pancreatic head Jpn. J. Surg. 19 510 518
4. T Nagakawa M Kayahara K Ueno 1992 A clinicopathologic study on neural invasion in cancer of the pancreatic head Cancer 69 930 935
5. J Mollenhauer I Roether HP Kern 1987 Distribution of extracellular matrix proteins in pancreatic ductal adenocarcinoma and its influence on tumor cell proliferation in vitro Pancreas 2 14 24
6. CJ Yeo JL Cameron KD Lillemoe 1995 Pancreaticoduodenectomy for cancer of the head of the pancreas Ann.Surg. 221 721 731
7. A Martinez-Hernandez PS Amenta 1983 The basement membrane in pathology Lab. Invest. 48 656 677
8. CS Lee J Montebello T Georgiou 1994 Distribution of type IV collagen in pancreatic adenocarcinoma and chronic pancreatitis Int. J. Exp. Pathol. 75 79 83
9. Z-H Wang T Manabe G Ohshio 1994 Immunohistochemical study of heparin sulfate proteoglycan in adenocarcinoma of the pancreas Pancreas 9 758 763
10. M Schmitt N Harbeck C Thomssen 1997 Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy Thromb. Haemost. 78 285 -296
11. PA De Bruin G Griffioen HW Verspaget 1988 Plasminogen activator profiles in neoplastic tissues of the human colon Cancer Res. 48 4520 4524
12. V Costantini A Sidoni R Deveglia 1996 Combined overexpression of urokinase, urokinase receptor and plasminogen activator inhibitor-1 is associatied with breast cancer progression; an immunohistochemical comparison of normal, benign, and malignant breast tissues Cancer 77 1079 1085
13. D Collen 1997 Thrombin therapy Thromb. Haemost. 78 742 746
14. F Blasi 1999 Proteolysis, cell adhesion, chemotaxis, and invasiveness are regulated by the u-PA-u-PAR-PAI-1 system Thromb. Haemost. 82 298 304
15. DH Berger 2002 Plasmin/plasminogen system in colorectal cancer World J. Surg. 26 767 771
16. PA Andreasen L Kjoller L Christensen 1997 The urokinase-type plasminogen activator sytem in cancer metastasis: a review Int. J. Cancer. 72 1 22
17. MD Boyle R Lottenberg 1997 Plasminogen activation by invasive human pathogens Thromb. Haemost. 77 1 10
18. G Liu MA Schuman RL Cohen 1995 Co-expression of urokinase-plasminogen activator and plasminogen activator inhibitor-1 is necessary for optimum invasiveness of cultured lung cancer cells Int. J. Cancer 60 501 506
19. N Tarbe S Losch H Burtscher 2002 Identification of rat pancreatic carcinoma genes associated with lymphogenous metastasis Anticancer Res. 22 2015 2027
20. V Ellenrieder SF Hendler C Ruhland 2001 TGF-beta-induced invasiveness of pancreatic cancer cells is mediated by matrix metalloproteinases-2 and the urokinase plasminogen activator system Int. J.Cancer. 93 204 211
21. H Teraoka T Sawada Y Yamashita 2001 TGF-beta1 promotes liver metastasis of pancreatic cancer by modulating the capacity of cellular invasion Int. J.Oncol. 19 709 715
22. H Zhang T Morisaki H Matsunaga 2000 Protein-bound polysaccharide PSK inhibits tumor invasiveness by down-regulation of TGF-betal and MMPs Clin. Exp. Metastasis 18 343 352
23. D Albo DH Berger GP Tuszynski 1998 The effect of thrombospondin-1 and TGF-beta 1 on pancreatic cancer cell invasion J. Surg. Res. 76 86 90
24. D Cantero H Friess J Deflorin 1997 Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma Br. J. Cancer 75 388 395
25. Y Takeuchi A Nakao A Harada 1993 Expression of plasminogen activators and their inhibitors in human pancreatic carcinoma: immunohistochemical study Am. J. Gastroenterol. 88 1928 1933
26. R Paciucci M Tora VM Diaz 1998 The plasminogen activator system in pancreas cancer: role of tPA in the invasive potential in vitro Oncogene 16 625 633
27. VM Diaz J Planaguma TM Thompson 2001 Tissue plasminogen activator is required for the growth, invasion and angiogenesis of pancreatic tumor cells Gastroenterology 122 806 819
28. J Yamashita M Ogawa M Abe 1997 Tumor neutrophil elastase is closely associated with the direct extension of non-small cell lung cancer into the aorta Chest 111 885 890
29. P Shamamian JD Schwartz BJ Pocok 2001 Activation of progelatinase A (MMP2) by neutrophil elastase, cathepsin G, and proteinase-3: a role for inflammatory cells in tumor invasion and angiogenesis J. Cell. Physiol. 189 197 206
30. H Kamohara K Sakamoto S Mita 1997 Neutrophil elastase inhibitor (ONO-5046.Na) suppresses the proliferation, motility, and chemotaxis of a pancreatic cell line, Capan-1 Res. Commun. Mol. Pathol. Pharmacol. 98 103 108
31. K Iwase M Miyata T Yamaguchi 1993 Pancreatic ductal cell carcinoma producing pancreatic elastase 1 J. Surg. Oncol. 54 199 202
32. H Zhou A Sziegoleit HP Fischer 1995 Immunocytochemical localization of elastase I in human pancreas Histochem. Cell Biol. 103 103 109
33. H Yamamura M Tatsuta M Ito 1989 Effectiveness of discriminant analysis of serum CA19-9 and elastase 1 in diagnosis of pancreatic carcinoma Pancreas 4 401 405
34. T Hayakawa T Kondo T Shibata 1990 Prospective trial for early detection of pancreatic cancer by elevated serum immunoreactive elastase Gastroenterol. Jpn. 25 727 731
35. T Kimura T Ito T Sumii 1991 Characteristic behavior of serum elastases 1 in pancreatic cancer Fukuoka Igaku Zasshi 82 355 361
36. L Gullo R Pezzilli M Ventrucci 1989 Serum immunoreactive elastase: is it useful for the diagnosis of pancreatic cancer? Pancreas 4 334 338
37. XY Zhao SY Yu SP Da 1998 A clinical evaluation of serological diagnosis for pancreatic cancer World J. Gastroenterol. 4 147 149
38. R Hoekstra FA Eskens J Verweij 2001 Matrix metalloproteinase inhibitors: current developments and future prospectives Oncologist 6 415 427
39. C He SM Wilhelm AP Pentland 1989 Tissue cooperation in a proteolytic cascade activating human interstitial collagenase Proc. Natl. Acad. Sci. U.S.A. 86 2632 2636
40. Y Okada Y Gonoji K Naka 1992 Matrix Metalloproteinase 9 (92-kDa gelatinase/type IV collagenase) from HT 1080 human fibrosarcoma cells: purification and activation of the precursor and enzymatic properties J. Biol. Chem. 276 21712 21719
41. G Murphy MI Cockett PE Stephens 1987 Stromelysin is an activation or procollagenase Biochem. J. 248 265 268
42. S Bramhall 1998 Stromal degration by the malignant epithelium in pancreatic cancer and the therapeutic potential of proteolytic inhibition J. Hepato biliary Pancreat. Surg. 5 392 401
43. DW Cottam RC Rees 1993 Regulation of matrix metalloproteinases: their role in tumor invasion and metastasis Int. J. Oncol. 2 861 872
44. L Jones P Ghaneh M Humphreys 1999 The matrix metalloproteinases and their inhibitors in the treatment of pancreatic cancer Ann. N.Y. Acad. Sci. 880 288 307
45. Y Okumura H Sato M Seiki 1997 Proteolytic activation of the precursor of membrane type 1 matrix metalloproteinase by human plasmin: a possible cell surface activator FEES Lett. 402 181 184
46. H Sato T Takino Y Okada 1994 A matrix metalloproteinase expressed on the surface of invasive tumour cells Nature 370 61 65
47. MP D'Ortho H Will K Atkinson 1997 Membrane-type matrix metalloproteinases 1 and 2 exhibit broad-spectrum proteolytic capacities comparable to many matrix metalloproteinases Eur. J. Biochem. 250 751 757
48. AE Kossakowska SA Huschcroft S Urbanski 1996 Comparative analysis of the expression patterns of MMPS and their inhibitors in breast neoplasia, sporadic colorectal neoplasia, pulmonary cancer and malignant non-Hodgkin's lymphoma in humans Br. J. Cancer 73 1401 1408
49. R Poulsom AM Hanby M Pignatelli 1993 Expression of gelatinase A and TIMP-2 mRNAs in desmoplastic fibroblasts in both mammary carcinomas and basal cell carcinomas of the skin J. Clin. Pathol. 46 429 436
50. R Poulsom M Pignatelli WG Stetler-Stevenson 1992 Stromal expression of 72 kDa type IV collagenase (MMP-2) and TIMP-2 mRNAs in colorectal neoplasia Am. J. Pathol. 141 389 396
51. PD Brown RE Bloxidge NS Stuart 1993 Association between expression of activated 72-kilodalton gelatinase and tumor spread in non-small-cell lung carcinoma J. Natl. Cancer Inst. 85 574 578
52. A Ponton B Coulombe D Skup 1991 Decreased expression of tissue inhibitor of metallproteinases in metastatic tumor cells leading to increased levels of collagenase activity Cancer Res. 51 2138 2143
53. Y DeClerck N Perez H Shimada 1992 Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases Cancer Res. 52 701 708
54. T Koshiba R Hosotani Y Wada 1998 Involvement ofMMP2 activity in invasion and metastases of pancreatic tissue Cancer 82 642 650
55. SR Bramhall GWH Stamp J Dunn 1996 Expression of collagenase (MMP2), stromeolysin (MMP3), and tissue inhibitor of the metalloproteinases (TIMP1) in pancreatic and ampullary disease Br. J. Cancer 73 972 978
56. TM Gress F Muller-Pillasch MM Lerch 1995 Expression and in situ localization of genes coding for extracellular matrix degrading proteases in pancreatic cancer Int. J. Cancer 62 407 413
57. C Wild-Bode M Weller A Rimner 2001 Sublethal irradiation promotes migration and invasiveness of glioma, cells: implications for radiotherapy of human glioblastoma Cancer Res. 61 2744 2750
58. LW Qian K Mizumoto T Urashima 2002 Radiation-induced increase in invasive potential of human pancreatic cells and its blockade by a matrix metalloproteinase inhibitor, CGS2702 Clin. Cancer Res. 8 1223 1227
59. G Bergers R Brekken G McMahon 2000 Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis Nat. Cell. Biol. 2 737 744
60. Y Matsuyama S Takao T Aikou 2002 Comparison of matrix metalloproteinase expression between primary tumors with or without liver metastasis in pancreatic and colorectal carcinomas J. Surg. Oncol. 80 105 110
61. H Yamamoto F Itoh S Iku 2001 Expression of matrix metalloproteinases and tissue inhibitors in human pancreatic adneocarcinomas: clinicopathologic and prognostic significance of matrilysin expression J. Clin. Oncol. 19 1118 1127
62. HC Crawford CR Scoggins ML Washington 2002 Matrix metalloproteinase-7 is expressed by pancreatic cancer precursors and regulates acinar-to-ductal metaplasia in exocrine pancreas J. Clin. Invest. 109 1437 1444
63. T Imamura G Ohshio M Mise 1998 Expression of membrane-type matrix metalloproteinase-1 in human pancreatic adenocarcinomas J. Cancer Res. Clin. Oncol. 124 65 72
64. V Ellenrieder B Alber U Lacher 2000 Role of MT-MMPs and MMP-2 in pancreatic cancer progression Int. J. Cancer. 85 14 20
65. M Yokoyama K Ochi M Ichimura 2002 Matrix metalloproteinases-2 in pancreatic juice for diagnosis of pancreatic cancer Pancreas 24 344 347
66. EE Zervos AE Shafii M Haq 1999 Matrix Metalloproteinase inhibition suppresses MMP-2 activity and activation of PANC-1 cells in vitro J. Surg. Res. 84 162 167
67. K Iki T Tomoyuki T Kubozoe 2002 Detection of serum MMPs in tumor-bearing hamsters J. Hepatobiliary Pancreat. Surg. 9 478 484
68. T Ito M Ito J Shiozawa 1999 Expression of the MMP-1 in human pancreatic carcinoma: relationship with prognostic factor Mod. Pathol. 12 669 674
69. H Nakamura S Horita N Senmaru 2002 Association with matrilysin expression with progression and poor prognosis in human pancreatic adenocarcinoma Oncol. Rep. 9 751 755
70. JD Evans P Ghaneh A Kawesha 1997 Role of matrix metalloproteinases and their inhibitors in pancreatic cancer Digestion 58 520 528
71. A Rosemurgy J Harris A Langleben 1999 Marimastat in patients with advanced pancreatic cancer: a dose-finding study Am. J. Clin. Oncol. 22 247 252
72. JD Evans A Stark CD Johnson 2001 A phase II trial of marimastat in advanced pancreatic cancer Br. J. Cancer 85 1865 1870
73. MJ Moore H Hamm P Eisenberg 2003 Comparison of gemcitabine versus the matrix - metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group J. Clin. Oncol. 21 3296 3302
74. S Zucker J Cao WT Chen 2000 Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment Oncogene 19 6642 6650
75. SR Bramhall J Schulz J Nemunaitis 2002 A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as a first line therapy in patients with advanced pancreatic cancer Br. J. Cancer 87 161 167
76. J-M Su Y-Q Wei L Tian 2003 Active immunogene therapy of cancer with vaccine on the basis of chicken homologous matrix metalloproteinase-2 Cancer Res. 63 600 607